“Delivering on navenibart’s best-in-class potential is our top priority, and enrollment in the global Phase 3 ALPHA-ORBIT trial is well underway with active sites across the U.S., U.K., Canada, Hong Kong, and South Africa” said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics (ATXS). “We are encouraged by the strong enthusiasm from patients and physicians, including at the recent HAEA conference, where we had the opportunity to engage with the HAE community. We were also thrilled to announce a strategic partnership with Kaken. Their expertise supports our ongoing Phase 3 enrollment, contributes to strengthening our financial position, and may ultimately help expand global patient access to navenibart.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
- ATXS Earnings this Week: How Will it Perform?
- Astria Therapeutics: Strategic Partnership and Promising Phase 3 Trial Justify Buy Rating
- Astria Therapeutics’ Strategic Advancements and Market Potential: A Buy Recommendation by Joseph Pantginis
- Astria Therapeutics licenses navenibart rights in Japan to Kaken Pharmaceutical
- Astria Therapeutics Enters Licensing Deal with Kaken